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Aims: The demand for oral anticoagulant therapy will continue to increase in the future along 
with the aging of the population. This study aimed to determine the rate of bleeding requiring 
hospitalization and to characterize early bleeders among persons initiating warfarin therapy. 
Characterization of those most susceptible to early bleeding is important in order to increase 
the safety of warfarin initiation.
Patients and methods: Using data from nationwide health registers, we identified persons 
initiating warfarin therapy between January 1, 2009 and June 30, 2012, n=101,588, and followed 
them until hospitalization for bleeding, death, or administrative end of the study (December 31, 
2012). We defined early bleeders as persons with a bleeding requiring hospitalization within 
30 days since warfarin initiation.
Results: The rate of hospitalization for bleeding during a median follow-up of 1.9 years was 
2.6% per person-year (95% confidence interval [CI] 2.5%–2.7%), with a peak within the first 
30 days of warfarin initiation (6.5% per person-year, 95% CI 6.0%–7.1%). In a multivari-
able Cox proportional hazards regression analysis, early bleeders were characterized by prior 
bleeding (180 days before initiation, hazard ratio [HR] =13.7, 95% CI 10.9–17.1; during 
180 days–7 years before initiation, HR =1.48, 95% CI 1.15–1.90), male sex (HR =1.32, 95% CI 
1.10–1.57), older age (HR =1.13, 95% CI 1.04–1.22, per 10-year increase), venous thrombosis 
(HR =1.83, 95% CI 1.44–2.34), pulmonary embolism (HR =1.46, 95% CI 1.11–1.91), alcohol 
abuse (HR =1.59, 95% CI 1.08–2.35), rheumatic disease (HR =1.40, 95% CI 1.07–1.83), and 
exposure to drugs with dynamic interaction mechanism with warfarin (HR =1.43, 95% CI 
1.20–1.71). In age-adjusted models, Charlson comorbidity index and number of drugs predicted 
a graded increase in the hazard of early bleeding.
Conclusion: The rate of hospitalizations for bleeding peaked in the beginning of warfarin 
therapy. Early bleeders were characterized by venous thrombosis, pulmonary embolism, and 
factors that increase bleeding risk without affecting the international normalized ratio.
Keywords: bleeding, comorbidity, hemorrhage, incidence, warfarin
Introduction
Vitamin K antagonists, especially warfarin, have traditionally been a cornerstone of 
anticoagulation therapy in the prevention and treatment of thromboembolic events. 
The main indication for warfarin therapy is atrial fibrillation (40%–65% of patients), 
followed by venous thrombosis, pulmonary embolism, and heart valve replacement.1–4 
Despite its well-established efficacy,5,6 warfarin therapy also involves a substantial 
risk of bleeding. In observational studies representing real-world clinical practice, the 
incidence of bleeding ranges from 1.9% to 7.6% per person-year (PY) among patients 
with atrial fibrillation receiving warfarin therapy.4,7–16
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The incidence of bleeding has been shown to peak in the 
beginning of warfarin therapy,11,17 being the highest during 
the first month after warfarin initiation.11 The early peak 
may arise from early attrition of those most susceptible 
to bleeding.18 In addition, it may be related to difficulty to 
achieve the narrow therapeutic range (international normal-
ized ratio [INR] 2–3). Specifically, warfarin dose–response 
is influenced by many factors, such as patient’s age, diet, 
and various drugs and comorbidities that may alter warfarin 
metabolism.19 In addition, polymorphisms in CYP2C9 and 
VKORC1 genes have an important contribution to warfa-
rin dose–response.20 While INR above therapeutic range 
(INR .3) is a significant risk factor for bleeding,21 more than 
half of bleeding events occur within or below therapeutic 
range.22,23 Other factors, such as comorbidities and drugs, that 
increase bleeding risk without altering warfarin metabolism 
or activity of coagulation factors can contribute to these 
events; therefore, they cannot be avoided by INR monitoring 
and subsequent changes in warfarin dosing. Characterization 
of those most susceptible to early bleeding is important in 
order to increase the safety of warfarin initiation.
In this nationwide population-based cohort study, we 
examined the rate of serious bleeding, defined as bleeding 
requiring hospitalization, among noninstitutionalized Finnish 
persons initiating warfarin therapy over up to 4 years of 
follow-up. In addition, we characterized persons with an early 
bleeding requiring hospitalization in terms of comorbidities 
and exposure to interacting drugs.
Patients and methods
setting and data sources
We conducted a nationwide population-based cohort study 
among noninstitutionalized Finnish persons initiating 
warfarin therapy between January 1, 2009, and June 30, 
2012. We followed the initiators from the warfarin initia-
tion date until December 31, 2012. We assembled the data 
by linking nationwide health registers maintained by the 
Social Insurance Institution (SII) and the National Institute 
for Health and Welfare (THL). The SII provided data on 
dispensed prescription drugs, demographics, dates of death, 
special reimbursements, and long-term institutional care 
(.90 days of uninterrupted stays in public nursing homes or 
hospitals). The THL provided data on hospitalizations.
The Prescription Register includes information on reim-
bursed prescription drugs dispensed to community-dwelling 
residents of Finland.24 The information on drug use in public 
nursing homes and hospitals is supplied by the service pro-
vider and, therefore, not covered by the Prescription Register. 
For each reimbursed drug, the Prescription Register contains 
Anatomical Therapeutic Chemical classification code,25 
dispensing date, strength, and quantity dispensed. No struc-
tured information on prescribed dose, duration of therapy, or 
indication is recorded. Furthermore, the Prescription Register 
contains data neither on nonreimbursed nor over-the-counter 
drugs (eg, low-dose acetylsalicylic acid). According to 
Finnish reimbursement rules, drugs can be reimbursed for a 
maximum of 3 months supply at one dispensing.26 The Spe-
cial Reimbursement Register contains information on entitle-
ments to special reimbursement (either 65% or 100% of drug 
costs in 2015) due to certain severe and chronic diseases. In 
order to be eligible for special reimbursement, a patient’s 
disease must meet explicit criteria proved by a certificate 
from a physician. The Hospital Discharge Register contains 
information on hospital admissions, including inpatient 
care, day surgeries, and specialized outpatient care in public 
hospitals.27 Data on diagnoses and medical procedures are 
registered using the International Classification of Diseases 
(ICD) codes (ICD-10 since 1996) and the Nordic Medico-
Statistical Committee classification of surgical procedures.
Warfarin initiators
Using data from the Prescription Register, we identified per-
sons initiating warfarin therapy between January 1, 2009 and 
June 30, 2012. We defined initiators as persons who filled a 
prescription for warfarin during the study period but had not 
been dispensed warfarin within the previous 365 days. We 
excluded persons who had been in long-term institutional 
care any time preceding warfarin initiation and persons with 
a hospital stay lasting continuously for .90 days during the 
365 days preceding warfarin initiation in order to confirm 
that our cohort of initiators did not include persons who may 
have used warfarin earlier during long-term institutional or 
hospital care.
Warfarin exposure
Due to the lack of data on the duration of warfarin prescrip-
tions, we present the rate of bleedings requiring hospital-
ization for the entire follow-up and separately for the first 
warfarin episode. To estimate the length of the first warfarin 
episode, we determined a fixed duration for each warfarin 
prescription using the waiting time distribution (WTD) 
method.28 Specifically, we identified prevalent warfarin 
users in 2012, defined as those who had been dispensed 
warfarin also in 2011, and determined the number of days 
(since January 1, 2012) in which 80% of these prevalent 
users were dispensed warfarin for the first time in 2012. 
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Then, we assigned each warfarin prescription a fixed duration 
obtained this way (111 days). Warfarin episode was deemed 
to continue until the gap between consecutive dispensations 
exceeded 111 days. Our WTD estimate was similar for both 
dose sizes of warfarin (103 days for 3 mg and 115 days for 
5 mg) and robust over time (110–113 days using data from 
2009 to 2011). In Finland, warfarin is available in packages 
of 100 tablets only. To allow for doses less than one tablet 
per day, periodic dose adjustments, and interruptions in home 
medication for various reasons, we conducted a sensitiv-
ity analysis extending the fixed duration assigned for each 
prescription to 180 days.11 That is, the first warfarin episode 
was assumed to continue until the gap between consecutive 
dispensations exceeded 180 days.
Bleeding events
We determined a bleeding event as an admission to 
hospital for bleeding. We identified relevant admissions 
on the basis of primary discharge diagnoses using a list 
of ICD-10 codes adapted from Gomes et al11 (Table S1). 
We categorized bleeding events further as intracranial, 
gastrointestinal, and others. We defined early bleeders as 
persons with a bleeding event within 30 days of warfarin 
initiation. The rest of the warfarin initiators were defined 
as nonearly bleeders, including those with bleeding event 
later than 30 days of warfarin initiation and those without 
bleeding event during the follow-up. We defined fatal 
bleeding events as those where the patient died within 
10 days of the hospital admission.
indications, comorbidities, and 
medications
We determined indications, comorbidities, and medications 
at warfarin initiation date based on data on hospital admis-
sions, special reimbursement codes, and/or dispensed drugs 
captured from the nationwide health registers (Figure 1). 
Detailed ICD codes, reimbursement codes, and Anatomical 
Therapeutic Chemical classification codes are available in 
Table S1. To describe bleeding risk, we combined data on 
age, sex, and malignancy.29 To define stroke risk (congestive 
heart failure, hypertension, age 75, diabetes and stroke 
[CHADS
2
], reflects stroke risk in patients with atrial fibrilla-
tion not receiving anticoagulant therapy), we combined data 
on heart failure, hypertension, age 75 years, diabetes, and 
ischemic stroke/transient ischemic attack.30 We determined 
Charlson comorbidity index by identifying 17 comorbidities 
based on hospital admissions over a 1-year period preceding 
the warfarin initiation date.31
interacting drugs
We determined exposure to interacting drugs at warfarin 
initiation date (Figure 1). A person was considered as 
exposed if interacting drug prescription overlapped with the 
warfarin initiation date or was filled at the warfarin initiation 
Indicationsa Hospital admission
1 year
1 year
1 year
Overlap
7 years
3 months
Warfarin
initiation
Hospital admission
Special reimbursement
Special reimbursement
Prescription dispensed
Prescription dispensed
Prescription overlap
Comorbiditiesb
Medicationsc
Interacting drugsd
Figure 1 Measurement of indications, comorbidities, medications, and exposure to interacting drugs.
Notes: aa hospital admission within a 1-year period before or at the warfarin initiation date, or a valid entitlement to special reimbursement at the warfarin initiation date, 
or within a 3-month period after the warfarin initiation date. ba hospital admission within a 7-year period before or at the warfarin initiation date, or a valid entitlement to 
special reimbursement at the warfarin initiation date, or a prescription dispensed within a 1-year period before or at the warfarin initiation date. ca prescription dispensed 
within a 1-year period before or at the warfarin initiation date. da prescription overlapped with the warfarin initiation date, or a prescription dispensed at the warfarin 
initiation date.
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date. We identified drugs having potential for clinically 
 significant interaction with warfarin from the Swedish, 
Finnish, Interaction X-referencing drug–drug interaction 
database.32 We defined the duration of each interacting drug 
prescription (except those for antimicrobials) based on the 
quantity dispensed, assuming a dosage equal to one defined 
daily dose per day.25 However, we truncated the duration to 
100 days, that is, the maximum duration of treatment reim-
bursed at one dispensing.26 Finally, we multiplied the duration 
by 1.5 to allow for nonadherence. We defined the duration of 
each prescription for antimicrobials as 7 days.
analyses
We calculated the rate of bleeding events for the entire 
follow-up by dividing the number of persons with a bleed-
ing event by the sum of PYs of follow-up. The follow-up 
started from the warfarin initiation and lasted until the first 
bleeding event, death, or administrative end of the study 
(December 31, 2012), whichever occurred first. The rate 
of bleeding events for the first 14-day period and for each 
30-day period (months) starting from warfarin initiation was 
calculated among those alive at the beginning of the period 
and without bleeding event in the previous periods. In the 
site-specific analyses of bleeding rate (intracranial, gastro-
intestinal, and other), bleeding events in other sites did not 
cause censoring of follow-up. In addition, we calculated the 
rate of bleeding events during the first warfarin episode; the 
follow-up started from the warfarin initiation date and lasted 
until the end of the first warfarin episode, the first bleeding 
event, long-term institutional care, or .90-day admission to 
hospital, death, or administrative end of the study, whichever 
occurred first.
We characterized early bleeders and nonearly bleeders 
by known and potential risk factors for bleeding measured 
by the register data at warfarin initiation, including age, sex, 
indication for warfarin therapy, bleeding history, comorbidi-
ties, medications, Charlson comorbidity index, bleeding risk 
score, CHADS
2
 score, and exposure to interacting drugs.
In addition, we performed age-adjusted and multivariable-
adjusted Cox proportional hazards regression analyses to 
determine characteristics associated with an early bleeding 
event, expressing the results as hazard ratios (HRs) and their 
95% confidence intervals (CIs). The potential  predictors 
were age, sex, indications for warfarin therapy, history of 
any bleeding requiring hospitalization 180 days before and 
during 180 days–7 years before warfarin initiation, individual 
comorbidities, Charlson comorbidity index, number of drugs 
in use during the year preceding warfarin initiation, and expo-
sure to interacting drugs at warfarin initiation. The results 
of the multivariable analyses are presented with and without 
adjustment for the Charlson comorbidity index (as this index 
includes many of the separately measured disease states) and 
the number of drugs (as the number of drugs is also a measure 
of overall morbidity). The bleeding risk and CHADS
2
 scores 
are combinations of age and other variables already in the 
model; therefore, these scores were excluded from the age-
adjusted and multivariable-adjusted analyses.
The proportional hazards assumption was checked both 
graphically and by testing the significance of the interac-
tion term between the predictor and logarithmic time. The 
assumption was found to be reasonably fulfilled except for 
the variable history of any bleeding requiring hospitaliza-
tion 180 days before warfarin initiation. This variable 
was included in the multivariable Cox proportional hazards 
models as a stratifying variable. In addition, we performed 
multicollinearity diagnostics for all the predictors included 
in the multivariable Cox models; we did not observe any 
sign of strong multicollinearity as the values of the variance 
inflation factor were 5 for all predictors.
Ethical issues
This study was institutionally approved by SII and THL. As 
the research team received only deidentified data and the 
patients were not contacted, consent was neither required by 
SII or THL, nor sought by the authors.
Results
A total of 102,048 persons initiated warfarin therapy between 
January 1, 2009 and June 30, 2012. We excluded 460 persons 
as they had been in long-term institutional care before warfa-
rin initiation or were continuously hospitalized for .90 days 
during the preceding year. Finally, our study population 
consisted of 101,588 warfarin initiators.
rate of bleeding events
Of warfarin initiators, 5,354 were hospitalized for a bleed-
ing during the entire follow-up of 204,592 PYs (median 
1.9 years, interquartile range [IQR]: 1.1–2.9 years), result-
ing in a rate of 2.6% per PY (Table 1). The rate was the 
highest early after warfarin initiation, being 7.9% per PY 
(95% CI 7.05%–8.8%) for the first 14 days and 6.5% per 
PY (95% CI 6.0%–7.1%) for the first 30 days. After the first 
12 months, the rate stabilized ∼2% per PY (Figure 2). Among 
warfarin initiators, 81.7% (n=83,046) discontinued therapy 
during the follow-up and half of them (n=43,750) after the 
first warfarin prescription. The median duration of the first 
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warfarin episode was 5.5 months (IQR: 3.7–9.5 months). 
The number of initiators with a bleeding event during 
the first warfarin episode (altogether 69,656 PYs) was 
2,283, resulting in a rate of 3.3% per PY (95% CI 3.1–3.4). 
When the first warfarin episode was assumed to continue 
until the gap between consecutive prescriptions exceeded 
180 days (instead of 111 days), the median duration of the 
episode was 10.6 months (IQR: 6–20.1 months) and the 
rate of any bleeding requiring hospitalization was 3.0% per 
PY (95% CI 2.9–3.1). Figure S1 shows the rate of bleeding 
events during the first warfarin episode on the assumptions 
of prescription duration of 111 and 180 days.
The rate of bleeding events during the entire follow-up 
was similar across indications (from 2.9% to 3.1% per PY), 
with the exception of lower rate among those with venous 
thrombosis (2.1% per PY, 95% CI 2.0–2.3). The rate of 
bleeding events within the first 30 days of warfarin initia-
tion was the highest among those with pulmonary embolism 
(10.9% per PY 95% CI 8.4%–13.9%) or venous thrombosis 
(10.2% per PY, 95% CI 8.3%–12.5%).
Table 1 Rate of bleedings requiring hospitalization (% per PY) among warfarin initiators during the first 30 days after initiation and 
during the entire follow-up (n=101,588)
Bleeding site First 30 days Entire follow-up
Number of bleeders Rate, % per PY (95% CI) Number of bleeders Rate, % per PY (95% CI)
any bleeding 539 6.5 (6.0–7.1) 5,354 2.6 (2.5–2.7)
intracranial bleeding 83 1.0 (0.8–1.2) 920 0.4 (0.4–0.5)
gastrointestinal bleeding 192 2.3 (2.0–2.7) 1,874 0.9 (0.9–0.9)
Other bleeding 267 3.2 (2.8–3.6) 2,721 1.3 (1.3–1.4)
Abbreviations: CI, confidence interval; PY, person-year.
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Figure 2 rate of bleedings requiring hospitalization during the entire follow-up for each month starting from warfarin initiation (n=101,588).
Abbreviation: PY, person-year.
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The distribution of bleeding site was similar among all 
5,354 bleeding events and among 539 early bleeding events, 
with 16% of bleeding events being intracranial, ∼35% 
 gastrointestinal, and ∼49% other bleedings. Overall, 5.3% 
(n=283) of all bleeding events (200 of intracranial, 68 of 
gastrointestinal, and 15 of other bleeding events) and 2.6% 
(n=14) of early bleeding events were fatal (eight of intracra-
nial, five of gastrointestinal, and one of other bleedings).
Characteristics of early bleeders
Among 539 early bleeders, 74.0% were 65 years and 
56.4% were men. Nonearly bleeders were younger and less 
frequently men than early bleeders (Table 2). Approximately 
40% of both early bleeders and nonearly bleeders had 
atrial fibrillation. One-third of early bleeders (31.0%) and 
less than one-tenth of nonearly bleeders (7.4%) had a his-
tory of bleeding. Most of the addressed comorbidities and 
medications were more common among early bleeders than 
among nonearly bleeders. In addition, early bleeders were 
more frequently exposed to interacting drugs (67.5%) than 
nonearly bleeders (57.1%) (Table 3). The hazard of early 
bleeding did not increase consistently with an increasing 
value of the bleeding risk score (Table 2). Among those 
identified as patients with atrial fibrillation, a CHADS
2
 
score .2 predicted an 87% increase in the hazard of early 
bleeding.
Based on multivariable Cox proportional hazards regres-
sion analysis, those with a history of bleeding were most 
likely to experience an early bleeding (Table 4). The HR 
for early bleeding associated with the history of bleeding 
during 180 days–7 years before warfarin initiation variable 
was 1.48 (95% CI 1.15–1.91). When history of bleeding 
within 180 days prior to initiation was not treated as a 
stratifying variable, its (average) HR was 13.7 (95% CI 
10.9–17.1). In addition, early bleeders were characterized 
by older age (HR =1.13, 95% CI 1.04–1.22, per 10-year 
increase in age), male sex (HR =1.32, 95% CI 1.10–1.57), 
venous thrombosis (HR =1.83, 95% CI 1.44–2.34), pul-
monary embolism (HR =1.46, 95% CI 1.11–1.91), alcohol 
abuse (HR =1.59, 95% CI 1.08–2.35), rheumatic disease 
(HR =1.40, 95% CI 1.07–1.83), and exposure to drugs with 
dynamic mechanism of interaction with warfarin (HR =1.43, 
95% CI 1.20–1.71). When the model was further adjusted 
for Charlson  comorbidity index and the number of drugs 
in use during the past year, the preceding associations were 
slightly attenuated and the HR for rheumatic disease was 
not significant any more. In age-adjusted models, Charl-
son comorbidity index and number of drugs predicted 
a steep graded increase in the hazard of early bleeding; 
these associations were attenuated when adjusted for other 
predictors.
Discussion
In this population-based cohort study, we found that the 
rate of bleeding leading to hospitalization was 2.6% per PY 
among noninstitutionalized Finnish persons initiating warfa-
rin therapy over a median of 1.9 years of follow-up. The rate 
of bleeding requiring hospitalization peaked within the first 
month of warfarin initiation (6.5% per PY), especially among 
those with pulmonary embolism or venous thrombosis. 
One-third of early bleeders had a history of bleeding. Besides 
being characterized by prior bleeding, pulmonary embolism, 
or venous thrombosis, early bleeders were older, male, had 
history of alcohol abuse or rheumatic disease, and were 
using drugs with pharmacodynamic interaction mechanism 
with warfarin.
The rate of bleeding hospitalizations was higher dur-
ing the first warfarin episode (3.0%–3.3% per PY) than 
during the entire follow-up (2.6% per PY). This may result 
from the fact that ∼40% of the initiators discontinued therapy 
after the first prescription, and therefore, the first warfarin 
episode emphasized the beginning of therapy when the rate 
of bleeding was the highest. In addition, the difference may 
arise from the fact that the entire follow-up included person-
time after warfarin discontinuation. However, the incidence 
of bleeding may not decrease immediately after the end of 
warfarin therapy since factors leading to discontinuation 
may be related to the appearance of early signs of bleeding. 
One previous study showed a minor increase in the bleeding 
incidence during the first month after warfarin discontinua-
tion, but a decrease thereafter.10
Our estimates on the rate of bleeding among warfarin ini-
tiators fall within the range of 1.9%–7.6% per PY, which was 
reported previously by observational studies among patients 
with atrial fibrillation receiving warfarin therapy.4,7–16 Differ-
ences in the rates between the studies may largely emerge due 
to differences in the definitions of bleeding, the age distribu-
tion of the study populations, and the length of follow-up (as 
the incidence peaks in the beginning of warfarin therapy). 
Moreover, many studies have not excluded persons with prior 
warfarin exposure, resulting in the  underestimation of early 
events. In our study, the rate of bleeding among those with 
verified atrial fibrillation was 2.9% per PY during the first 
warfarin episode (data not shown), being somewhat smaller 
than that (3.8% per PY) reported in a Canadian study with a 
similar definition for bleeding events among patients with 
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Table 2 Characteristics of early bleeders (n=539) and nonearly bleeders (n=101,049) at the warfarin initiation date
Characteristics Early bleeders Nonearly bleeders Unadjusted HR (95 % CI)
Demographics
 Men 56.4 (304) 51.5 (52,018) 1.22 (1.03–1.45)
 age, years, median (iQr) 73 (64–81) 72 (62–80) 1.10 (1.03–1.17)a
  #64 26.0 (140) 30.8 (31,081) 1.00 (reference)
  65–74 27.5 (148) 26.5 (26,799) 1.23 (0.97–1.54)
  75 46.6 (251) 42.7 (43,169) 1.29 (1.05–1.59)
indications
 Atrial fibrillation 37.9 (204) 40.1 (40,560) 0.91 (0.76–1.08)
 Venous thrombosis 17.6 (95) 11.2 (11,272) 1.70 (1.36–2.12)
 Mechanical heart valve 12.1 (65) 12.0 (12,144) 1.00 (0.78–1.30)
 Pulmonary embolism 12.2 (66) 7.3 (7,357) 1.78 (1.37–2.30)
 ischemic stroke or transient ischemic attack 11.5 (62) 8.9 (8,985) 1.33 (1.02–1.73)
history of bleeding
 any bleeding 31.0 (167) 7.4 (7,523) 5.53 (4.61–6.64)
 1 day–180 days before warfarin initiation 20.0 (108) 1.3 (1,345) 17.9 (14.5–22.2)
 180 days–7 years before warfarin initiation 14.3 (77) 6.4 (6,490) 2.42 (1.90–3.08)
 intracranial bleeding 6.7 (36) 0.7 (663) 10.6 (7.57–14.9)
 gastrointestinal bleeding 8.9 (48) 2.9 (2,933) 3.25 (2.42–4.38)
 Other bleeding 17.1 (92) 4.2 (4,207) 4.70 (3.75–5.88)
Comorbidities
 Coronary artery disease 45.8 (247) 43.0 (43,445) 1.12 (0.95–1.33)
 heart failure 19.3 (104) 17.0 (17,179) 1.17 (0.95–1.45)
 ischemic stroke or transient ischemic attack 17.3 (93) 14.1 (14,260) 1.27 (1.01–1.59)
 hypertension 51.6 (278) 46.3 (46,782) 1.24 (1.04–1.46)
 Peripheral arterial disease 6.3 (34) 4.6 (4,657) 1.40 (0.99–1.98)
  Thrombosis in cerebral arteries or in intracranial veins 1.1 (6) 1.2 (1,190) 0.95 (0.42–2.11)
 Diabetes 18.6 (100) 18.2 (18,431) 1.02 (0.82–1.27)
 renal impairment 4.6 (25) 2.5 (2,497) 1.92 (1.29–2.87)
 liver disease 2.2 (12) 1.0 (1,047) 2.17 (1.23–3.85)
 Dementia 4.8 (26) 4.6 (4,691) 1.05 (0.71–1.55)
 Malignancy 17.4 (94) 13.6 (13,742) 1.34 (1.08–1.68)
 alcohol abuse 5.8 (31) 3.0 (3,009) 1.98 (1.38–2.85)
 Pulmonary disease 18.9 (102) 16.0 (16,121) 1.23 (0.99–1.53)
 rheumatic disease 11.7 (63) 7.1 (7,122) 1.74 (1.34–2.27)
 gastrointestinal disease 42.3 (228) 31.3 (31,612) 1.61 (1.36–1.91)
 Charlson comorbidity index, median (iQr) 1 (0–2) 0 (0–1) 1.27 (1.19–1.36)
Medications
 number of drugs, median (iQr) 10 (7–14) 9 (6–12) 1.82 (1.55–2.13)b
 any cardiovascular drug 86.3 (465) 85.0 (85,908) 1.11 (0.87–1.42)
 antithrombotic drugs 40.5 (218) 26.9 (27,180) 1.84 (1.55–2.19)
 lipid-modifying drugs 44.5 (240) 43.2 (43,697) 1.05 (0.89–1.25)
Bleeding risk scorec
 0 11.3 (61) 13.4 (13,497) 1.00 (reference)
 1.3–1.6 40.3 (217) 38.5 (38,865) 1.24 (0.93–1.64)
 2.2–2.9 32.1 (173) 35.1 (35,503) 1.08 (0.81–1.45)
 3.5 16.3 (88) 13.0 (13,184) 1.48 (1.07–2.05)
ChaDs2 score
d (among those with atrial fibrillation, n=40,764)
 0 11.8 (24) 18.9 (7,662) 1.00 (reference)
 1 26.0 (53) 27.6 (11,191) 1.51 (0.93–2.45)
 2 30.4 (62) 26.1 (10,577) 1.87 (1.17–3.00)
 3 31.9 (65) 27.4 (11,130) 1.87 (1.17–2.98)
Notes: Data shown as percentage (n), median (iQr), or unadjusted hr (95 % Ci). hrs reported for presence versus absence of a characteristic unless otherwise stated. 
aPer 10 years. bPer one unit increase in the number of drugs measured on a logarithmic scale. cBleeding risk score defined based on age, sex, and malignancy, and ranges from 
0 to 5.1.32 dChaDs2 score reflects the risk of stroke in persons with atrial fibrillation, defined based on heart failure, hypertension, age 75 years, diabetes, stroke/transient 
ischemic attack, and ranges from 0 to 6.33
Abbreviations: ChaDs2, congestive heart failure, hypertension, age 75, diabetes and stroke; CI, confidence interval; HR, hazard ratio; IQR, interquartile range.
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Table 3 Exposure to interacting drugs at the warfarin initiation date 
among early bleeders (n=539) and nonearly bleeders (n=101,049)
Interacting drugs Early  
bleeders, % (n)
Nonearly 
bleeders, % (n)
any interacting drug 67.5 (364) 57.1 (57,731)
 One interacting drug 37.9 (204) 35.5 (35,902)
 Two interacting drugs 21.0 (113) 15.8 (15,958)
 Three or more interacting drugs 8.7 (47) 5.8 (5,871)
any drug with dynamic  
mechanism of interaction
53.3 (287) 41.1 (41,493)
 Paracetamol 26.2 (141) 19.4 (19,574)
 Prednisolone 9.1 (49) 5.9 (5,907)
 levothyroxine 7.6 (41) 6.8 (6,863)
 Clopidogrel 5.8 (31) 3.2 (3,278)
 ibuprofen 5.6 (30) 5.3 (5,310)
 Citalopram 3.5 (19) 2.5 (2,546)
 Etoricoxib 3.0 (16) 1.5 (1,497)
 Escitalopram 2.6 (14) 1.6 (1,627)
 Tramadol 2.4 (13) 2.1 (2,166)
 Diclofenac 1.3 (7) 1.3 (1,348)
 naproxen 0.7 (4) 1.0 (1,023)
 Dexamethasone 1.3 (7) 0.4 (356)
 Methylprednisolone 1.5 (8) 0.5 (503)
 Meloxicam 0.9 (5) 0.8 (837)
 Venlafaxine 0.6 (3) 0.6 (610)
any drug with kinetic  
mechanism of interaction
3.3 (18) 3.3 (3,299)
 amiodarone 0.9 (5) 1.0 (1,014)
 Fluvastatin 0.7 (4) 1.4 (1,377)
any drug with unclear  
mechanism of interaction
27.1 (146) 24.8 (25,055)
 simvastatin 24.5 (132) 22.9 (23,180)
 rosuvastatin 2.2 (12) 2.0 (2,003)
 Ciprofloxacin 0.9 (5) 0.6 (586)
 Levofloxacin 1.3 (7) 0.6 (607)
 Doxycycline 0.6 (3) 0.7 (652)
Notes: Persons were considered as exposed if interacting drug prescription 
overlapped with the warfarin initiation date. individual drugs with a prevalence 
of 0.5% in both early and nonearly bleeders are excluded.
atrial fibrillation during their first warfarin episode.11 We used 
a stricter definition for a bleeding event (identified based on 
primary discharge diagnoses only) and our study population 
was younger, which may explain the difference in the rates.
The peak in the bleeding rate in the beginning of warfarin 
therapy may arise from difficulty to achieve the target INR.18 
However, in the absence of data on INR values, we were 
unable to assess whether early bleedings occurred at INR 
above the therapeutic range. In Finland, persons on warfarin 
therapy have been reported to spend on an average ∼13% 
of the time above the therapeutic range,33,34 but there are no 
data whether this proportion is higher in the beginning of 
therapy. In a British study, time spent above the therapeutic 
range was 20% in the first month after warfarin initiation 
and ∼15% in the following 2 years,35 suggesting that the time 
spent above the therapeutic range varies modestly across the 
duration of therapy.
The early peak in the rate of bleeding may further 
result from the early attrition of those most susceptible to 
bleeding.18 We found that early bleeders were character-
ized by prior bleeding, older age, history of alcohol abuse, 
and exposure to drugs with pharmacodynamic interaction 
mechanism with warfarin, all of which increase the bleed-
ing risk without affecting the INR. Therefore, the initiation 
of warfarin therapy in the presence of these characteristics 
requires particular consideration and monitoring, as well 
as careful evaluation of prior medication. Unfortunately, 
we could not evaluate the exposure to low-dose acetylsali-
cylic acid, the use of which is common among warfarin 
initiators13 and has been associated with an increased 
bleeding risk during warfarin therapy.12,36,37 In addition, 
it should be noted that early bleeders may have suffered 
from undiagnosed and untreated comorbidities, such as 
peptic ulcer or malignancy, that have predisposed them 
to bleeding.
The peak in the rate of bleeding during the first month 
after warfarin initiation was most prominent among per-
sons with pulmonary embolism (10.9% per PY) or venous 
thrombosis (10.2% per PY). We do not have an explicit 
explanation for our observation, but it could be related to 
the fact that those with pulmonary embolism or venous 
thrombosis were more frequently exposed to nonsteroidal 
anti-inflammatory drugs (NSAIDs) at warfarin initiation 
(13.1% and 18.3%, respectively) than those receiving war-
farin for other indications (7.2%–8.9%); however, when we 
added NSAID use at warfarin initiation to our multivari-
able model, the HRs for venous thrombosis or pulmonary 
embolism did not change (data not shown). In addition, 
those with pulmonary embolism or venous thrombosis may 
have been exposed to higher warfarin doses, an important 
risk factor for bleeding.38 Nonetheless, those with venous 
thrombosis and pulmonary embolism had higher rates of 
bleeding events only in the beginning of warfarin therapy, 
not during the entire follow-up. This accords with previ-
ous studies not illustrating a higher incidence of bleeding 
among those with venous thrombosis compared with other 
indications.4,39
Early bleedings were further predicted by rheumatic 
disease. Persons with rheumatic disease were commonly 
exposed to corticosteroids (29.2%) and NSAIDs (17.8%) 
at warfarin initiation; however, the inclusion of the use of 
NSAIDs in the multivariable model did not affect the HR for 
early bleeding associated with rheumatic disease.
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Table 4 Factors associated with early bleeding among warfarin initiators (n=101,588)
Factors Age-adjusted HR  
(95% CI)
Multivariable-adjusted  
HR (95% CI)a
Multivariable-adjusted 
HR (95% CI)b
sex
 Men 1.30 (1.09–1.55) 1.32 (1.10–1.57) 1.34 (1.11–1.60)
age
 Per 10 years na 1.13 (1.04–1.22) 1.12 (1.04–1.21)
indications
 Atrial fibrillation 0.87 (0.73–1.03) 1.00 (0.83–1.21) 0.98 (0.81–1.19)
 Venous thrombosis 1.94 (1.54–2.44) 1.83 (1.44–2.34) 1.80 (1.41–2.92)
 Mechanical heart valve 1.04 (0.80–1.34) 0.99 (0.76–1.30) 0.95 (0.73–1.24)
 Pulmonary embolism 1.85 (1.43–2.40) 1.46 (1.11–1.91) 1.42 (1.09–1.87)
  ischemic stroke or transient ischemic attack 1.31 (1.01–1.71) 1.22 (0.93–1.61) 1.04 (0.77–1.39)
history of bleeding
  During 1 day–180 days before warfarin initiation 17.7 (14.3–21.9) na na
  During 180 days–7 years before warfarin initiation 2.35 (1.84–2.99) 1.48 (1.15–1.90) 1.46 (1.14–1.88)
Comorbidities
 Coronary artery disease 1.04 (0.87–1.24) 1.00 (0.82–1.21) 0.95 (0.78–1.15)
 heart failure 1.10 (0.88–1.37) 1.04 (0.83–1.31) 0.93 (0.73–1.18)
 hypertension 1.17 (0.98–1.39) 1.13 (0.94–1.35) 1.07 (0.89–1.29)
 Peripheral arterial disease 1.34 (0.94–1.90) 1.11 (0.78–1.59) 1.04 (0.73–1.49)
  Thrombosis in cerebral arteries or in intracranial veins 0.97 (0.43–2.16) 0.75 (0.33–1.68) 0.72 (0.32–1.62)
 Diabetes 0.99 (0.80–1.24) 0.88 (0.70–1.10) 0.79 (0.63–1.01)
 renal impairment 1.87 (1.25–2.79) 1.22 (0.81–1.85) 1.09 (0.71–1.67)
 liver disease 2.27 (1.28–4.02) 1.40 (0.77–2.56) 1.29 (0.71–2.36)
 Dementia 0.92 (0.62–1.38) 0.89 (0.60–1.34) 0.82 (0.55–1.23)
 Malignancy 1.28 (1.02–1.60) 1.06 (0.85–1.34) 0.94 (0.74–1.20)
 alcohol abuse 2.18 (1.51–3.15) 1.59 (1.08–2.35) 1.55 (1.05–2.28)
 Pulmonary disease 1.21 (0.97–1.50) 1.05 (0.84–1.31) 0.95 (0.75–1.19)
 rheumatic disease 1.70 (1.31–2.21) 1.40 (1.07–1.83) 1.30 (0.99–1.71)
 gastrointestinal disease 1.58 (1.33–1.87) 1.10 (0.92–1.33) 1.02 (0.84–1.24)
Charlson comorbidity index
 0 1.00 na 1.00
 1–3 1.74 (1.46–2.07) na 1.32 (1.06–1.65)
 4–9 3.14 (2.08–4.74) na 1.66 (0.99–2.76)
number of drugs
 1–4 1.00 na 1.00
 5–9 1.82 (1.30–2.55) na 1.56 (1.10–2.20)
 10–14 2.16 (1.53–3.06) na 1.57 (1.06–2.31)
 15 3.14 (2.20–4.50) na 1.88 (1.20–2.93)
Exposure to interacting drugs
  Drugs with dynamic mechanism of interaction 1.63 (1.38–1.93) 1.43 (1.20–1.71) 1.32 (1.10–1.59)
  Drugs with kinetic mechanism of interaction 1.01 (0.63–1.61) 0.94 (0.59–1.52) 0.90 (0.56–1.44)
  Drugs with unclear mechanism of interaction 1.10 (0.91–1.34) 1.10 (0.90–1.33) 1.05 (1.05–2.28)
Notes: history of bleeding during 1 day180 days before warfarin initiation treated as a stratifying variable. aMutually adjusted for all variables except for Charlson 
comorbidity index and number of drugs; bmutually adjusted for all variables.
Abbreviations: CI, confidence interval; HR, hazard ratio; NA, not applicable.
In our study, the proportion of fatal bleedings was 
lower (5.3%) than those observed in previous studies 
(7.2%–18.1%).10,11 This was evident for the proportion of 
fatal intracranial bleedings as well (21.6% vs ∼40%),10,11 
suggesting that the lower proportion was not due to inclu-
sion of less severe bleedings. The lower proportion was 
also not due to younger study population since the pro-
portion of fatal bleedings increased only modestly (6.1%) 
when those aged 65 years were excluded. Furthermore, 
the lower proportion is not likely to be explained by our 
approach to include all indications since indication for 
warfarin therapy appears to have a limited impact on fatal-
ity of bleeding.39
Methodological considerations
The strengths of our study include a large study sample 
representative to noninstitutionalized Finnish population, 
up-to-date data, and comprehensive data sources. In addition, 
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by following initiators, instead of prevalent warfarin users, 
we were able to detect the early peak in the rate of bleeding. 
In addition, our data are from the time before non-vitamin K 
antagonist oral anticoagulants became reimbursable among 
patients with atrial fibrillation, pulmonary embolism, or 
venous thrombosis,40 and therefore, our cohort represents 
the whole range of oral anticoagulant initiators.
Some limitations need to be noted. First, we did not 
have data on minor bleedings that did not result in hospi-
tal admission or fatal bleedings leading to death without 
hospital admission, resulting in underestimation of the 
rate of bleeding events. Second, there are no validation 
studies dealing with the quality of the Hospital Discharge 
Register for bleeding events except for intracranial hem-
orrhage. Overall, the completeness and accuracy of this 
register have been shown to be at least satisfactory and 
good in case of intracranial hemorrhage.24 The present 
study identified bleeding-related hospital admissions with 
primary ICD-10 codes, which decreases the likelihood of 
misclassification of patient’s prior bleeding as an event. 
Clinically, it is reasonable to assume that major bleedings 
are coded accurately. In fact, one Canadian validation 
study showed that the ICD codes have good sensitivity 
(93%), specificity (88%), and positive predictive (91%), 
and negative predictive values (91%) for the identification 
of warfarin-related bleedings when compared to medical 
records.41 Third, our data of indications and comorbidities 
are not complete since they were based on administrative 
health registers, and we did not have access to primary 
care registers.42 Such misclassification may have diluted 
the observed associations between comorbidities and 
the hazard of early bleeding. Fourth, as in any study 
based on pharmacy dispensation data, we have no way 
of knowing whether and when the dispensed warfarin 
was actually consumed. In the absence of data on INR 
monitoring, we could not assess whether early bleeding 
events were related to supratherapeutic INR values. As 
we had no information on the duration of each warfarin 
prescription, we used a data-driven WTD as a proxy and 
conducted sensitivity analyses extending the prescription 
duration to 180 days. The main and sensitivity analyses 
produced similar results. In addition, we do not know 
whether the exposure to interacting drugs continued after 
warfarin initiation. Nevertheless, we previously showed 
that the interacting drugs are frequently prescribed 
within the first month of warfarin initiation,43 suggesting 
that warfarin initiation seldom results in the discontinua-
tion of interacting drugs, with the exception of NSAIDs.40 
Moreover, we may have underestimated exposure to ibu-
profen, ketoprofen, and paracetamol as small packages are 
available over the counter. Finally, exposure to low-dose 
acetylsalicylic acid (over-the-counter product), alternative 
medications, dietary factors, smoking, and alcohol was 
out of reach in our study.
Conclusion
Our population-based cohort study indicated that the rate 
of bleeding was the highest in the beginning of warfarin 
therapy. Persons most susceptible to an early bleeding were 
characterized by venous thrombosis and pulmonary embo-
lism and factors that increase bleeding risk without alteration 
in the INR. Therefore, the initiation of warfarin therapy in 
the presence of these factors requires careful consideration 
and monitoring.
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Table S1 Identification of bleeding events, indications, comorbidities, and medications
Bleeding events, indications, 
comorbidities and medications
ICD-10 codes/procedure codes Reimbursement codes ATC codes
Bleedingsa
 intracranial i60*, i61*, i62*
 gastrointestinal K920, K921, K922, i850, K221, K250, K252,  
K254, K256, K260, K262, K264, K266, K270,  
K272, K274, K276, K280, K282, K284, K286,  
K290, K625
 Other n02*, K661, n938, n939, n950, r041,  
r042, r048, r049, r31, r58, D683,  
h356, h431, h450, M250
indications
 Atrial fibrillation i48*, FPD*, TFP46, TFP20 207 (based on i48)
 Venous thrombosis i80*, i81*, i82* (not i801)
 Mechanical heart valve Z952*, FJ*, FK*, FM*, Fg*
 Pulmonary embolism i26*
 ischemic stroke/Tia i63*, g45*
Comorbidities
 Coronary artery disease i20*–i25*/Fna*, FnB*, FnC*, FnD*, FnE*,  
Fn1aT, Fn1BT, Fn1YT, TFn40, TFn50
206 C01
 heart failure i50* 201
 ischemic stroke/Tia i63*–i66*, g45*
 hypertension i10*–i15* 205
 Peripheral arterial disease i70*, i74*/PFh*, PDQ*, PEQ*, PFQ*,  
PF1aT, PF1BT, PE1aT, PE1BT
211
  Thrombosis in cerebral arteries  
or in intracranial veins
i65*, i66*, i676  
 Diabetes E10*–E14* 103 a10
 renal impairment n04*, n17*–n19*, n258, Z491, Z492 123, 137, 138, 190, 320
 liver disease K70*–K77*, B15*–B19*, B942
 Dementia F00*, F01*, F03*, g30* 307 n06D
 Malignancy C00*–C99*, D00*–D09* 115–117, 128, 130 l01*, l02B* (not l01Ba01)
 alcohol abuse E244, F10*, g312, g4051, g621, g721,  
i426, K292, K70*, K852, K860, r780, T510,  
Y911, Y912, Y913, Y919, Z502, Z714
 n07BB
 Pulmonary disease J44*–J46* 203 r03
 rheumatic disease M05*–M09*, M13*, M31*–M36*, M45*, M46* 202, 281, 313
 gastrointestinal disease K21*, K223, K251, K253, K255, K257,  
K259, K261, K263, K265, K267, K269,  
K271, K273, K275, K277, K279, K281,  
K283, K285, K287, K289, K633
a02B
Medications
 number of drugs number of different aTC-codes
 any cardiovascular drug C01–C04, C07–C09
 antithrombotic drugs B01 (not B01aa03)
 lipid-modifying drugs C10
Notes: aData adapted from Gomes T, Mamdani MM, Holbrook AM, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ. 2013;185(2):E121–E127.1 
Codes i9820, i983, K6380, and K3180 were excluded as they do not appear in the Finnish iCD-10 codes. *includes all the diagnoses from the given iCD-10 code.
Abbreviations: ATC, Anatomical Therapeutic Chemical; ICD, International Classification of Diseases; TIA, transient ischemic attack.
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Warfarin therapy and bleeding
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Figure S1 Rate of bleedings requiring hospitalization for each month of the first 
warfarin episode when the episode was assumed to continue until the gap between 
consecutive dispensations exceeded 111 days (A) or 180 days (B).
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